Literature DB >> 21796804

Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow.

Jia-Hui Li1, Peng Yang, Ai-Li Li, Yong Wang, Yuan-Nan Ke, Xian-Lun Li.   

Abstract

OBJECTIVE: To evaluate whether liposomal prostaglandin E1 (lipo-PGE1) can decrease reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction (AMI).
METHODS: Twenty-two male Chinese mini-swines were randomized into three groups: six in a sham-operation group, and eight each in the control and lipo-PGE1 groups. The distal part of the left anterior descending coronary artery (LAD) in the latter two groups was completely occluded for 2 h, and then reperfused for 3 h. Lipo-PGE1 (1 μg/kg) was injected 10 min before LAD occlusion until reperfusion for 1 h in the lipo-PGE1 group. Hemodynamic data and proinflammatory cytokines were examined before AMI, 2 h after occlusion, and 1, 2, and 3 h after reperfusion. Myocardial contrast echocardiography (MCE) and double staining were performed to evaluate the myocardial no-reflow area (NRA).
RESULTS: Left ventricular systolic pressure and end-diastolic pressure significantly improved in the lipo-PGE1 group after reperfusion compared with the control group and also 2 h after AMI (P<0.05 for both). MCE and double staining both showed that lipo-PGE1 decreased reperfusion NRA after AMI (P<0.05, P<0.01). Lipo-PGE1 decreased serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) after myocardial infarction reperfusion (P<0.05 for both).
CONCLUSIONS: Lipo-PGE1 is cardioprotective in our porcine model of myocardial infarction reperfusion no-reflow, decreasing NRA and attenuating the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796804      PMCID: PMC3150717          DOI: 10.1631/jzus.B1101007

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  10 in total

1.  Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.

Authors:  I Morishima; T Sone; K Okumura; H Tsuboi; J Kondo; H Mukawa; H Matsui; Y Toki; T Ito; T Hayakawa
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

2.  Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention.

Authors:  Ronen Jaffe; Thierry Charron; Geoffrey Puley; Alexander Dick; Bradley H Strauss
Journal:  Circulation       Date:  2008-06-17       Impact factor: 29.690

3.  Minimally invasive close-chest method for creating reperfused or occlusive myocardial infarction in swine.

Authors:  Gabriele A Krombach; Sylvia Kinzel; Andreas H Mahnken; Rolf W Günther; Arno Buecker
Journal:  Invest Radiol       Date:  2005-01       Impact factor: 6.016

4.  Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery.

Authors:  T Kawamura; N Nara; M Kadosaki; K Inada; S Endo
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

5.  Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodelling in a rat model of acute myocardial infarction.

Authors:  Jian-an Wang; Rong-hua Luo; Xing Zhang; Xiao-jie Xie; Xin-yang Hu; Ai-na He; Jie Chen; Jia-hui Li
Journal:  J Zhejiang Univ Sci B       Date:  2006-08       Impact factor: 3.066

6.  In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk.

Authors:  Yoriyasu Suzuki; Jennifer K Lyons; Alan C Yeung; Fumiaki Ikeno
Journal:  Catheter Cardiovasc Interv       Date:  2008-01-01       Impact factor: 2.692

7.  Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model.

Authors:  R W Smalling; S Feld; N Ramanna; J Amirian; P Felli; W K Vaughn; C Swenson; A Janoff
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

8.  [Prostaglandin E1 reduces reperfusion injury of myocardium by inhibiting cytokines production during cardiac surgery].

Authors:  Zheng-fu He; Zhi-jun Li
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2004-07

9.  A novel minimal-invasive model of chronic myocardial infarction in swine.

Authors:  Thorsten Reffelmann; Oezgun Sensebat; Yochai Birnbaum; Ewa Stroemer; Peter Hanrath; Barry F Uretsky; Ernst R Schwarz
Journal:  Coron Artery Dis       Date:  2004-02       Impact factor: 1.439

10.  Validity of myocardial infarction models.

Authors:  H A Fozzard
Journal:  Circulation       Date:  1975-12       Impact factor: 29.690

  10 in total
  4 in total

1.  Alprostadil Injection Attenuates Coronary Microembolization-Induced Myocardial Injury Through GSK-3β/Nrf2/HO-1 Signaling-Mediated Apoptosis Inhibition.

Authors:  Zhenbai Qin; Binghui Kong; Jing Zheng; Xiantao Wang; Lang Li
Journal:  Drug Des Devel Ther       Date:  2020-10-22       Impact factor: 4.162

2.  Effect of Intravenous Administration of Liposomal Prostaglandin E1 on Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.

Authors:  Li-Ye Wei; Xiang-Hua Fu; Wei Li; Xi-Le Bi; Shi-Ru Bai; Kun Xing; Yan-Bo Wang
Journal:  Chin Med J (Engl)       Date:  2015-05-05       Impact factor: 2.628

Review 3.  Multiple roles of dihomo-γ-linolenic acid against proliferation diseases.

Authors:  Xiaoping Wang; Huanping Lin; Yan Gu
Journal:  Lipids Health Dis       Date:  2012-02-14       Impact factor: 3.876

4.  Prostaglandin E₁ protects bone marrow-derived mesenchymal stem cells against serum deprivation-induced apoptosis.

Authors:  Kuan Zeng; Bao Ping Deng; Hui-Qi Jiang; Meng Wang; Ping Hua; Hong-Wu Zhang; Yu-Bin Deng; Yan-Qi Yang
Journal:  Mol Med Rep       Date:  2015-08-05       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.